Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 4/20 | 0.46 |
| ▸ | GSK3A | P49840 | 3/20 | 0.45 |
| ▸ | GSK3B | P49841 | 3/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 8/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28474959 | 0.80 | ALK (0.48) | ALKGSK3AGSK3BCDK2FGFR1 | |
| SCHEMBL14814007 | 0.78 | FGFR1 (0.39) | ALKFGFR1FGFR2HSD17B1HSD17B2 | |
| SCHEMBL14139641 | 0.77 | GSK3A (0.44) | ALKGSK3AGSK3BCDK2FGFR1 | |
| SCHEMBL14814114 | 0.76 | ESR1 (0.40) | ALKGSK3AGSK3BCDK2FGFR1 | |
| SCHEMBL14813675 | 0.75 | ESR1 (0.48) | GSK3BFGFR1FGFR2TNIKESR1 | |
| SCHEMBL16682103 | 0.72 | NPC1 (0.57) | ALKGSK3BFGFR1FGFR2HSD17B1 | |
| SCHEMBL4362509 | 0.71 | SIRT1 (0.40) | ALKGSK3AGSK3BCDK2FGFR1 | |
| SCHEMBL12344014 | 0.70 | ALK (0.38) | ALKGSK3AGSK3BCDK2FGFR1 | |
| SCHEMBL14814136 | 0.69 | FGFR1 (0.44) | ALKGSK3AGSK3BCDK2FGFR1 | |
| SCHEMBL1057179 | 0.69 | MEN1 (0.46) | ALKCDK2FGFR1FGFR2TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760862-A1 | 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI (FR) | 2014-08-06 | — | — | EP | disclosed |
| US-20130085128-A1 | 6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors | SANOFI (FR) | 2013-04-04 | — | — | US | disclosed |
| WO-2013045413-A1 | 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI (FR) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085128-A1 | 6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors | MAP3K1, MAP3K6, MAP4K2 | ALK 275/4885GSK3A 609/4885GSK3B 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.